MiMedx Group, Inc. (MDXG)
Stock Price Chart
Key Info
| Market Cap | 621.80M |
| Revenue (ttm) | 280.65M |
| Net Income (ttm) | -8.38M |
| Shares Out | 111.04M |
| EPS (ttm) | -0.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 30, 2020 |
| Last Price | $5.60 |
| Previous Close | $5.75 |
| Change ($) | -0.15 |
| Change (%) | -2.61% |
| Day's Open | 5.75 |
| Day's Range | 5.60 - 5.94 |
| Day's Volume | 17,737 |
| 52-Week Range | 2.95 - 7.67 |
More Stats
| Market Cap | 621.80M |
| Enterprise Value | 638.83M |
| Earnings Date (est) | Nov 4, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 111.04M |
| Float | 93.53M |
| EPS (basic) | -0.07 |
| EPS (diluted) | -0.08 |
| FCF / Share | -0.41 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 61.28M |
| Short Ratio | 21.80 |
| Short % of Float | 65.52% |
| Beta | 1.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 2.22 |
| PB Ratio | 28.17 |
| Revenue | 280.65M |
| Operating Income | -10.27M |
| Net Income | -8.38M |
| Free Cash Flow | -43.93M |
| Net Cash | -17.03M |
| Net Cash / Share | -0.15 |
| Gross Margin | 91.28% |
| Operating Margin | -3.66% |
| Profit Margin | -3.00% |
| FCF Margin | -15.65% |
| ROA | 7.58% |
| ROE | -35.27% |
| ROIC | -14.80% |
Analyst Forecasts
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 299 | 359 | 321 | 245 | 187 | 118 | 59.18 | 27.05 | 7.76 | 0.79 |
| Revenue Growth | -16.67% | 11.82% | 31.07% | 30.82% | 58.43% | 99.77% | 118.76% | 248.6% | 883.74% | - |
| Gross Profit | 256 | 323 | 286 | 213 | 167 | 106 | 49.85 | 21.87 | 4.40 | -0.93 |
| Operating Income | -21.16 | -3.92 | 46.22 | 18.11 | 24.36 | 7.10 | -2.64 | -3.79 | -9.76 | -10.53 |
| Net Income | -25.58 | -29.98 | 64.73 | 11.97 | 29.45 | 6.22 | -4.11 | -7.66 | -10.19 | -11.42 |
| Shares Outstanding | 107 | 106 | 106 | 106 | 106 | 106 | 96.29 | 81.65 | 72.45 | 59.14 |
| Earnings Per Share | -0.24 | -0.28 | 0.56 | 0.11 | 0.26 | 0.05 | -0.04 | -0.09 | -0.14 | -0.19 |
| EPS Growth | - | - | 409.09% | -57.69% | 420% | - | - | - | - | - |
| Operating Cash Flow | -39.41 | 35.80 | 62.94 | 25.83 | 18.81 | 16.80 | -0.28 | -3.33 | -6.66 | -8.16 |
| Capital Expenditures | -1.75 | -9.39 | -5.13 | -6.27 | -5.83 | -2.56 | -2.34 | -0.64 | -0.49 | -0.15 |
| Free Cash Flow | -41.16 | 26.41 | 57.81 | 19.56 | 12.98 | 14.24 | -2.62 | -3.97 | -7.15 | -8.31 |
| Cash & Equivalents | 69.07 | 45.12 | - | 34.39 | 31.49 | 52.33 | 44.08 | 6.75 | 4.11 | 1.34 |
| Total Debt | 65.66 | - | - | - | - | - | - | 4.01 | 5.17 | 0.40 |
| Net Cash / Debt | 3.41 | 45.12 | - | 34.39 | 31.49 | 52.33 | 44.08 | 2.74 | -1.06 | 0.94 |
| Assets | 167 | 123 | - | 193 | 136 | 109 | 84.69 | 35.18 | 27.10 | 7.35 |
| Liabilities | 133 | 73.19 | - | 60.26 | 27.93 | 19.93 | 11.13 | 15.18 | 15.20 | 1.25 |
| Book Value | 34.40 | 49.66 | - | 133 | 108 | 89.33 | 73.57 | 20.01 | 11.90 | 6.10 |
Company Profile
Company Details
| Full Name | MiMedx Group, Inc. |
| Country | United States |
| Employees | 696 |
| CEO | Timothy R. Wright |
Stock Information
| Ticker Symbol | MDXG |
| Stock Exchange | US OTC |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | OTCMKTS: MDXG |
Description
MiMedx Group, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, arterial ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill, a connective tissue matrix derived from placental disc, umbilical cord, and amnion/chorion tissues. Its products have applications in the areas of wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. The company sells its products through direct sales force, independent sales agents, and third party representatives, as well as independent distributors. MiMedx Group, Inc. is headquartered in Marietta, Georgia.